Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation

Circulation

Volumn 101, Issue 22, 2000, Pages 2612-2617

  Nakashima, Hideko ^a   Kumagai, Koichiro ^a   Urata, Hidenori ^a   Gondo, Naoki ^a   Ideishi, Munehito ^a   Arakawa, Kikuo ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

Angiotensin; Fibrillation; Remodeling

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATROPINE; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PROPRANOLOL;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFECT; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0034612362     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.22.2612     Document Type: Article

References (30)

1. Pfeffer JM, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival And Ventricular Enlargement trial. N Engl J Med. 1992;327:669-677.
2. Lui YH, Yang XP, Sharov VG, et al. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension. 1996;27:7-13.
3. Yoshiyama M, Kim S, Yamagishi H, et al. Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV116 on ischemia-reperfusion injury. Am Heart J. 1994;128:1-6.
4. Matsuo K, Kumagai K, Annoura M, et al. Effects of an angiotensin II antagonist on reperfusion arrhythmias in dogs. Pacing Clin Electrophysiol. 1997;20:938-945.
5. Harada K, Komuro I, Hayashi D, et al. Angiotensin II type 1a receptor is involved in the occurrence of reperfusion arrhythmias. Circulation. 1998; 97:315-317.
6. Pedersen OD, Bagger H, Kober L, et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 1999;100:376-380.
7. Wijffels MCEF, Kirchhof CJHJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation. 1995;92:1954-1968.
8. Goette A, Honeycutt C, Langberg JJ. Electrical remodeling in atrial fibrillation: time course and mechanisms. Circulation. 1996;94: 2968-2974.
9. Tieleman RG, Langen CDJD, Gelder ICVG, et al. Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation. 1997; 95:1945-1953.
10. Wijffels MCEF, Kirchhof CJHJ, Dorland R, et al. Electrical remodeling due to atrial fibrillation in chronically instrumented conscious goats: role of neurohumoral changes, ischemia, atrial stretch, and high rate of electrical activation. Circulation. 1997;96:3710-3720.
11. Fasciolo JC, Binia A. Angiotensin I, II, III tachyphylaxis in the mesenteric vascular circuit of the rat. Hypertension. 1981;3:166-170.
12. Tieleman RG, Gelder ICVG, Crijns HJGM, et al. Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodeling of the atria? J Am Coll Cardiol. 1998;31: 167-173.
13. Daoud EG, Knight BP, Weiss R, et al. Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans. Circulation. 1997;96:1542-1550.
14. + current in a chronic dog model of atrial fibrillation. Circ Res. 1997;81:1045-1052.
15. Yue L, Feng J, Gaspo R, et al. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res. 1997;81:512-525.
16. + channel blockade. J Interv Card Electrophysiol. 1998;2:15-23.
17. Chen YJ, Lee SH, Hsieh MH, et al. Effects of 17β-estradiol on tachycardia-induced changes of atrial refractoriness and cisapride-induced ventricular arrhythmia. J Cardiovasc Electrophysiol. 1999;10: 587-598.
18. Kaprielian RR, Dupont E, Hafizi S, et al. Angiotensin II receptor type 1 Mona is upregulated in atria of patients with end-stage heart failure. J Mol Cell Cardiol. 1997;29:2299-2304.
19. Webster MWI, Fitzpatrick A, Nicholls G, et al. Effect of enalapril on ventricular arrhythmias in congestive heart failure. Am J Cardiol. 1985; 56:566-569.
20. Gottlieb SS, Dickstein K, Fleck E, et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation. 1993;88:1602-1609.
21. Brock TA, Alexander RW, Ekstein LS, et al. Angiotensin increases cytosolic free calcium in cultured vascular smooth muscle cells. Hypertension. 1985;7:I-105-I-109.
22. Griendling KK, Rittenhouse SE, Brock TA, et al. Sustained diacylglycerol formation from inositol phospholipids in angiotensin II-stimulated vascular smooth muscle cells. J Biol Chem. 1986;261: 5901-5906.
23. Marrero MB, Paxton WG, Duff JL, et al. Angiotensin II stimulates tyrosine phosphorylation of phospholipase C-∂1 in vascular smooth muscle cells. J Biol Chem. 1994;269:10935-10939.
24. Ullian ME, Linas SL. Angiotensin II surface receptor coupling to inositol triphosphate formation in vascular muscle cells. J Biol Chem. 1990;265: 195-200.
25. Touyz RM, Sventek P, Lariviere R, et al. Cytosolic calcium changes induced by angiotensin II in neonatal rat atrial and ventricular cardiomyocytes are mediated via angiotensin II subtype 1 receptors. Hypertension. 1996;27:1090-1096.
26. Urata H, Healy B, Stewart RW, et al. Angiotensin II receptors in normal and failing human hearts. J Clin Endocrinol Metab. 1989;69:54-66.
27. Allen AM, Zhuo J, Mendelsohn FAO. Localization of angiotensin AT1 and AT2 receptors. J Am Soc Nephrol. 1999;10:S23-S29.
28. Urata H, Healy B, Stewart RW, et al. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res. 1990;66:883-890.
29. Daoud EG, Bogun F, Goyal R, et al. Effect of atrial fibrillation on atrial refractoriness in humans. Circulation. 1996;94:1600-1606.
30. Kumagai K, Matsuo K, Ono M, et al. Effects of verapamil on electrophysiological properties in paroxysmal atrial fibrillation. Pacing Clin Electrophysiol. 1993;16:309-316.